How much revenue does Unjha Formulations make?

Unjha Formulations reported 138.62 million INR in revenue for fiscal year 2025, down 25.1% from 184.96 million INR in fiscal year 2024. In Q3 2026 revenue was 44.08 million INR.

What companies are similar to Unjha Formulations?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Colinz Laboratories Limited (COLINZ.BO), Hemo Organic Limited (HEMORGANIC.BO), Desh Rakshak Aushdhalaya Ltd. (DESHRAK.BO), Norris Medicines Limited (NORRIS.BO).

Unjha Formulations Limited (UNJHAFOR.BO) Stock

About Unjha Formulations Limited

Unjha Formulations Limited manufactures and sells ayurvedic products in India. The company offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron, Fibron SF and Fibron SF (Sugar Free) names. It also exports its products. Unjha Formulations Limited was incorporated in 1994 and is based in Sidhpur, India.

At a glance

Unjha Formulations reported revenue of 138.62 million INR for fiscal year 2025, down 25.1% from fiscal year 2024, and net income of 4.08 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 44.08 million INR, up 17.2% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.